Articles tagged with Translational Research
Dr. Lorenz Studer is known for his pioneering advances in stem cell biology, regenerative medicine, and the development of stem cell-based therapies for neurodegenerative disease.
The Human Cancer Model Initiative released a compendium of more than 150 organoid models of 25 types of cancer, which are now available to scientists worldwide. These patient-derived organoids provide state-of-the-art research tools for accelerating discovery and developing personalized treatment strategies.
A new wearable electric-field device has been shown to slow the growth and spread of aggressive breast cancer in preclinical models. The technology uses low-intensity electric fields that interact with cancer cells in a controlled way, reducing tumor growth and increasing immune responses.
Massey Comprehensive Cancer Center awarded $2.7M K12 grant to support multidisciplinary cancer research and mentor early-stage clinical investigators. The grant aims to optimize participation by high-risk individuals in Virginia.
Researchers developed a framework to integrate AI into hospitals, emphasizing patient care, staff experience, and economic sustainability. The Total Mission Value framework aims to ensure high-quality patient care remains the top priority amidst AI's transformative potential.
A new drug, daraxonrasib, has been identified as a potential treatment for patients with NRAS-driven melanoma. The therapy targets and inhibits RAS protein, which drives cancer growth when mutated. Early results from preclinical models suggest the drug may be effective in treating advanced disease.
The symposium marked the hospital's designation as a research-oriented hospital, featuring discussions on collaborative research ecosystems at various levels. Participants engaged in sessions covering future directions, strengthening regional and industry collaborations, and real-world cases of research commercialization.
Researchers at Texas A&M University have found a way to intervene early in traumatic brain injuries using a natural, gut-derived chemical that prevents post-traumatic epilepsy from taking root. The treatment reduced brain inflammation, improved memory and mood, protected brain cells, made seizures both rarer and harder to trigger.
Researchers have developed a new drug candidate, SB-0110, that boosts L-dopa's benefits while reducing dyskinetic side effects in animal models of Parkinson’s disease. The compound preserves the gene-activity patterns tied to L-dopa’s benefits while counteracting biological changes associated with dyskinesia.
Researchers at Technion-Israel Institute of Technology discovered that mature, aged cells can revert into active stem cells that regenerate damaged tissue. This finding challenges the prevailing view on tissue regeneration and implies the possibility of therapies promoting natural healing mechanisms.
A Phase 1/2a clinical study demonstrates long-term survival of transplanted human neural progenitor cells in patients with retinitis pigmentosa, maintaining a favorable safety profile. Visual acuity remained stable, and imaging showed cells remaining present in the subretinal space for at least one year.
A new $250,000 grant will support the development of a novel therapeutic approach for sepsis-associated neurocognitive dysfunction. The treatment aims to protect the brain from inflammation-related damage during and after sepsis, potentially preventing or slowing neurodegeneration and cognitive decline.
The International Society for Stem Cell Research convenes its 2026 Annual Meeting in Montréal, showcasing groundbreaking discoveries and emerging clinical advances. The meeting features nearly 1,300 scientific posters and presentations spanning every area of stem cell research.
The Korea University College of Medicine and UNIST have been selected for the Ministry of Health and Welfare's K-MediST program, aiming to establish a leading model for integrated education and research in medical science and technology. The partnership will create an innovative interdisciplinary hub bridging medicine and engineering.
A new study published in Nature links casdatifan, an investigational HIF-2a inhibitor, to improved clinical outcomes in metastatic clear cell renal cell carcinoma (ccRCC) patients. Deep suppression of serum EPO correlated with higher response rates and longer progression-free survival.
Researchers at the German Center for Infection Research have developed a promising single-dose malaria treatment called SPAP, which targets the malaria parasite through multiple mechanisms. The four-drug combination therapy has shown significant promise in improving malaria treatment and could be a major advancement in sub-Saharan Africa.
The US retains its scientific edge but is losing the race to translate discoveries into cures, warns a new report from Cure Innovation Index. Without immediate renewed investment and policy changes, the US scientific edge will not hold.
Dr. Jennifer Guida, a renowned researcher and program director, has been appointed as the first director of HonorHealth Research Institute's Division of Institutional Research. She will oversee the institute's clinical trials efforts, providing patients with pioneering treatments based on internal research discoveries.
The University of Virginia has joined SPARK GLOBAL to leverage resources and expertise in accelerating the development of new medicines. This collaboration aims to reduce time from lab discoveries to clinic trials, delivering tangible healthcare solutions to patients.
The Columbia University Irving Medical Center has received a $75 million Clinical and Translational Science Award from the National Institutes of Health. This funding will support translational science at CUIMC, advancing biomedical research from bench to bedside.
Research waste refers to wasting scientific resources due to poor practices, compromising internal and external validity. JMIR Metascience and Research Integrity publishes metascience articles exploring the shortcomings of published literature and investigating its negative impact on real-world outcomes.
A study found that most persistent viral detection despite effective therapy is due to defective, non-infectious virus copies. The 5'-leader region of the virus is responsible for producing infectious particles, but defects in this area prevent the generation of functional viruses.
A pilot study of the Participant Engagement Portal (PEP) tool shows that 84% of participants had a positive experience, with high usability and satisfaction rates. PEP facilitates two-way communication between patients and clinicians, allowing for self-reporting of social risk factors and future research opportunities.
Researchers developed a senolytic therapy using dasatinib and quercetin, which preserved disc structure and reduced inflammation, highlighting JUN signaling as a key pathway. This preclinical study provides evidence for a potential therapeutic strategy to slow disease progression in individuals with genetic susceptibility.
The UMass Center for Clinical and Translational Science has received a seven-year, $50 million grant from the NIH. The funding supports collaboration among researchers at multiple UMass campuses and clinical partners.
Odylia Therapeutics is advancing a gene therapy treatment for Usher Syndrome Type 1C (USH1C)-associated vision loss, a rare autosomal recessive disorder. The grant will support the development of an investigational USH1C gene therapy designed to restore or preserve vision.
A new mRNA-based strategy amplifies the T-cell response to vaccines, enabling more powerful cancer vaccines and stronger protection against infectious diseases. The approach reprograms immune cells from within using mRNA instructions that expand cancer-fighting T cells.
Korea University College of Medicine has established a full-cycle physician-scientist training system from undergraduate studies to graduate school, fellowships, and professorships. The institution will further improve the path of physician-scientists with support from the Korea Health Industry Development Institute.
The summit brought together endocrine leaders to identify opportunities to work closely together on increasing the visibility of endocrine health in policy decisions. Early findings from a workforce survey revealed challenges including long patient waiting times and retention concerns among early-career clinicians.
A study of 308 participants found that those with higher baseline ePTFp concentrations experienced a significantly steeper decline in kidney function over time. This association remained significant even when serum phosphate concentrations were within normal range.
The Cure Innovation Index ranks top US biomedical institutions based on their ability to translate scientific discoveries into real-world healthcare solutions. The index identifies key factors such as commercialization infrastructure, industry engagement, and entrepreneurial culture that enable translational success.
A new targeted therapy has shown strong results in preclinical studies against aggressive childhood and adult cancers, eliminating tumours and stopping cancer spread. The therapy targets the IL1RAP protein, which is found on cancer cells but largely absent from normal tissues, allowing for precise delivery of treatment.
A study mapped early molecular and cellular changes in the jaw joint that may trigger temporomandibular joint osteoarthritis. The research found structural and molecular changes in joint tissues, including inflammation, fibrosis, and metabolic shifts. Single-cell sequencing revealed diverse cell populations interacting within the synov...
Lindsay Squeglia, Ph.D. of the Medical University of South Carolina received the 2026 ACTS Award for Supporting an Excellent Translational Science Workforce. She is a leading figure in substance use prevention and adolescent brain development research.
The Stem Cell Report podcast has marked five years of exploration in stem cell research, capturing significant progress in human development, disease, and regenerative medicine. The anniversary episode reunites past guests to discuss the field's evolution, highlighting advances in therapies, organoid systems, and global standards.
Scientists at the University of Virginia Health System have developed a suite of AI-powered tools, called YuelDesign, YuelPocket and YuelBond, to transform how new drugs are created. These tools can design drug molecules tailored to fit their protein targets exactly, even accounting for protein flexibility.
The San Antonio Breast Cancer Symposium generated nearly $40 million in economic impact and drew over 11,000 attendees from 104 countries. The symposium also produced $1.5 million in local tax revenue and supported more than 6,800 jobs.
The Accelerating Cancer Cures Research Symposium brings together Damon Runyon scientists and industry partners to foster communication and collaboration. The symposium features updates on research aimed at developing more precise targeted therapies for cancer treatment.
Researchers at Memorial Sloan Kettering Cancer Center discovered that skin stem cells possess a remarkable form of inflammatory memory that can last over a year. This finding has implications for understanding how repeated inflammation affects skin aging and disease susceptibility. The study used MSK-IMPACT, a tumor sequencing test, to...
The BiliSeq test detected approximately 82% of bile duct cancers, compared to 44% with pathology alone, and increased cancer detection to nearly 90% when combined with pathology. This improved accuracy enables physicians to provide more personalized medicine and treatment options for patients.
The University of Missouri is honoring three distinguished faculty members as 2025 AAAS Fellows. Paul de Figueiredo is being recognized for his contributions to microbiology, while Roman Ganta advances research on tick-borne diseases. Wesley Warren's expertise in genome-scale data analysis has reshaped research across multiple fields.
The BrainHealth Network connects researchers across the country to understand brain health improvement through advanced MRI imaging and data analysis. The network leverages a comprehensive multimodal brain imaging dataset, including a longitudinal study of 100,000 healthy participants over 10 years.
A multi-phase clinical study will examine dosing, safety and long-term effects of rapamycin in older adults to guide future research on extending health span. Researchers aim to establish evidence-based guidance for the drug's use and move beyond speculation.
A drug already in clinical trials for hepatitis C has been found to also prevent hepatitis E virus replication, offering new hope for a treatment option. The discovery was made using a library of nucleotide/nucleoside analogues and preclinical models.
The Terasaki Institute for Biomedical Innovation and UCLA Technology Development Group will co-curate an Advanced Organ and Tissue Repair (AToR) session at LABEST, featuring leading experts in regenerative medicine. The session aims to accelerate the translation of breakthrough technologies into real-world clinical solutions.
Dr. Gobbi challenges the global drug-development system, stating that promising treatments for mental illness are failing to reach patients due to venture capital and profit motives. Her research focuses on cannabis, melatonin, and psychedelics, with a goal of improving public-health decisions and treatment outcomes.
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
Severe COVID-19 and influenza infections can prime the lungs for cancer development, according to new research. Vaccination, however, largely prevents these changes, suggesting a reduced risk of lung cancer.
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
The partnership aims to accelerate biomedical innovation through joint research programs, faculty collaboration, and expanded student training opportunities. Researchers will have access to shared laboratory infrastructure, reciprocal faculty affiliations, and joint grant proposals.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
The Greaux Healthy initiative, launched by Pennington Biomedical Research Center, aims to prevent and treat childhood obesity in Louisiana. Studies show that childhood obesity is a national healthcare crisis in Louisiana, with over 1 in 3 children living with overweight or obesity.
Renowned cancer clinician Dr. Daniela Matei will lead the Houston Methodist Dr. Mary and Ron Neal Cancer Center, bringing expertise in ovarian cancer treatment and therapeutics. She aims to bridge laboratory science to the clinic, advancing new concepts from bench to bedside.
The foundation awarded $400,000 over two years to five early-career researchers and continuation support to three current Innovators with significant progress on their proposed research. The recipients focus on developing targeted therapeutics, decoding dendritic cell function, defining NKT cell interactions with tumors, engineering T ...
The International Society for Stem Cell Research has awarded the 2026 ISSCR Lifetime Achievement Award to Dr. Allen Eaves and late Dr. Connie Eaves, recognizing their groundbreaking work on blood stem cell biology, leukemia, and cancer stem cells. Their research and mentorship have profoundly influenced the field of stem cell science.
Aviv Regev, a pioneering computational biologist, will deliver a keynote address on tissue stem cells at the ISSCR 2026 Annual Meeting. Her work has transformed our understanding of cell and tissue function in health and disease.
The partnership aims to develop next-generation mRNA vaccines with enhanced stability and targeted delivery, providing broader protection against emerging pathogens. This collaboration combines Ethris' mRNA technology platforms with DZIF's vaccine research expertise to accelerate the development of variant-ready vaccines.
A team of researchers uses CRISPR gene editing to eliminate cells with amplified oncogenes, reducing tumour growth and increasing animal survival. The study offers a promising approach for precision therapies in resistant cancers.
The journal welcomes Bo Shen, Ph.D., and Luca Peruzzotti-Jametti, M.D., Ph.D. as Early Career Editors, bringing complementary strengths in stem cell niche biology and metabolism to the editorial board. Their perspectives will help ensure rigorous peer review, relevance, and global engagement.
The ACHILLES project trains researchers in experimental haematological oncology, developing advanced models, analysis tools, and therapeutic targets for leukaemia and lymphoma. The project aims to bridge basic and preclinical research with clinical practice, improving survival rates and accessibility to innovative treatments.